STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial

Eli Lilly's obesity drug retatrutide demonstrated weight loss comparable to bariatric surgery in Phase 3 trials, with patients losing up to 28.3% of body weight after 80 weeks. However, the treatment showed concerning side effects with 11% discontinuation rates on the highest dose, significantly higher than competing drugs like Wegovy and Zepbound.